The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

CPRIT grants $90M for cancer research, prevention across Texas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The governing board of the Cancer Prevention and Research Institute of Texas approved over $90 million in cancer research and prevention grants at its quarterly meeting on Feb. 15. The slate of forty projects from across Texas fund a wide range of research and prevention efforts at major research hubs like Dallas, San Antonio, and Houston, but also invests in rapidly developing cancer research programs in El Paso and the Rio Grande Valley.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: UPMC’s Byrd and Jefferson’s Chapman speak about avoiding catastrophism and using bridge funding to keep labs open
“There’s a tightening of the belt, and when the belt gets tightened, it has downstream effects.”

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.
By Claire Marie Porter and Paul Goldberg
In Brief

Christian Hinrichs, of Rutgers Cancer Institute & RWJBarnabas Health, receives V Foundation for Cancer Research award

Christian Hinrichs, co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence and chief of the Section of Cancer Immunotherapy, RWJBarnabas Health, has been awarded a four-year, $800,000 translational research grant from the V Foundation for Cancer Research to develop next-generation immunotherapies for cancers caused by human papillomavirus. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account